Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

Presentation ESC 2016

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Presenter: Raban V. Jeger

August 31, 2016

Presentation ESC 2016

“Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX

Presenter: Deepak L. Bhatt

August 31, 2016

Presentation ESC 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presenter: Zuzana Motovska

August 30, 2016

Presentation ESC 2016

Effective Anti-thrombotic Therapy without Stenting: Intravascular OCT-based Management in Plaque Erosion (the EROSION study)

Presenter: Ik-Kyung Jang

August 30, 2016

Presentation ESC 2016

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

Presenter: Andreas Goette

August 30, 2016

Presentation ESC 2016

DOCTORS: Does Optical Coherence Tomography Optimise Results of Stenting?

Presenter: Nicolas Meneveau

August 29, 2016

Presentation ESC 2016

CE-MARC 2 Trial: A Prospective, Multi-Centre, Randomized Trial Of 3 Diagnostic Strategies In Suspected Coronary Heart Disease (CMR vs UK NICE Guidelines vs MPS-SPECT)

Presenter: John P. Greenwood

August 29, 2016

Presentation ESC 2016

10-year outcomes of coronary artery bypass grafting vs medical therapy according to age: An update from the STICH trial

Presenter: Eric Velazquez

August 29, 2016

Presentation ESC 2016

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

Presenter: Javed Butler

August 28, 2016

Presentation ESC 2016

NIPPON Randomized Study: 6 Months vs 18 Months Dual Antiplatelet Treatment For Patients Underwent Bioabsorbable Polymer And Abluminal Coated DES Deployment

Presenter: Masato Nakamura

August 28, 2016

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Presentation ESC 2016

Feasibility and Safety of Direct Catheter - Based Thrombectomy in the Treatment of Acute Ischemic Stroke: Prospective Registry PRAGUE-16

Presenter: Petr Widimsky

August 27, 2016

Presentation ESC 2016

ESC-EAS Guidelines for the Management of Dyslipidaemias

Presenter: Ian Graham

August 27, 2016

Presentation ESC 2016

Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee for Practice Guidelines

Presenter: Patrizio Lancellotti

August 27, 2016

Presentation ESC 2015

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Presenter: Marco Valgimigli

September 01, 2015

Presentation ESC 2015

PLATFORM: IMpactsClinical outcomes of FFR-CT-guided diagnostic strategies versus usual care in patients with suspected coronary artery disease

Presenter: Pamela S. Douglas

September 01, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

Presentation ESC 2015

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

Presenter: Jacob A. Udell

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

Presentation ESC 2015

Peri-infarct Zone Pacing to Prevent Adverse Left Ventricular Remodeling in Patients with Large Myocardial Infarction: Results from the PRomPT Trial

Presenter: Gregg W. Stone

August 30, 2015

Advertisement

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

“Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Effective Anti-thrombotic Therapy without Stenting: Intravascular OCT-based Management in Plaque Erosion (the EROSION study)

Edoxaban vs Enoxaparin-Warfarin in Subjects UndergoingCardioversion of Atrial Fibrillation

DOCTORS: Does Optical Coherence Tomography Optimise Results of Stenting?

CE-MARC 2 Trial: A Prospective, Multi-Centre, Randomized Trial Of 3 Diagnostic Strategies In Suspected Coronary Heart Disease (CMR vs UK NICE Guidelines vs MPS-SPECT)

10-year outcomes of coronary artery bypass grafting vs medical therapy according to age: An update from the STICH trial

Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Heart Failure

NIPPON Randomized Study: 6 Months vs 18 Months Dual Antiplatelet Treatment For Patients Underwent Bioabsorbable Polymer And Abluminal Coated DES Deployment

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Feasibility and Safety of Direct Catheter - Based Thrombectomy in the Treatment of Acute Ischemic Stroke: Prospective Registry PRAGUE-16

ESC-EAS Guidelines for the Management of Dyslipidaemias

Cancer Treatments And Cardiovascular Toxicity Developed Under The Auspices Of The ESC Committee for Practice Guidelines

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

PLATFORM: IMpactsClinical outcomes of FFR-CT-guided diagnostic strategies versus usual care in patients with suspected coronary artery disease

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Long-term Dual Antiplatelet Therapy for 2° Prevention of Cardiovascular Events in Patients with Previous Myocardial Infarction

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Peri-infarct Zone Pacing to Prevent Adverse Left Ventricular Remodeling in Patients with Large Myocardial Infarction: Results from the PRomPT Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content